Synapse

← Cancer Research Communications

Papers in Cancer Research Communications

Page 5 · newest first

  1. Epithelial–Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell LinesCancer Research Communications · 2025
  2. Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable PrognosisCancer Research Communications · 2025
  3. Key early changes in oral squamous cell carcinogenesis are accelerated by ectopic BMI1 expressionCancer Research Communications · 2025
  4. Extrachromosomal microDNA Signature as Candidate Biomarker in Pediatric Acute Lymphoblastic LeukemiaCancer Research Communications · 2025
  5. Transcriptomic analyses of normal human pancreata reveal the presence of cancer subtypes that correlate with acinar ductal metaplasia and donor ancestryCancer Research Communications · 2025
  6. Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatinCancer Research Communications · 2025
  7. OPG-producing B Cells and RANKL-expressing T cells define immune signatures predictive of bone metastases in breast cancerCancer Research Communications · 2025
  8. SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor ProgressionCancer Research Communications · 2025
  9. Faecal sample collection for gut microbiome research in a prospective cohort: a pilot study within the Australian Breakthrough Cancer StudyCancer Research Communications · 2025
  10. Two molecular subgroups predict most recurrences in advanced laryngeal squamous cell carcinomaCancer Research Communications · 2025
  11. Copy number aberrations in circulating tumor DNA enable diagnosis and risk stratification of pediatric neuroblastic tumorsCancer Research Communications · 2025
  12. Roles of restricted mean survival time and restricted mean time lost in evaluating immune checkpoint inhibitor efficacy for extensive-stage small cell lung cancerCancer Research Communications · 2025
  13. Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated LiposarcomaCancer Research Communications · 2025
  14. Real-World Clinical Oncology Outcomes Associated With the Accelerated Approval PathwayCancer Research Communications · 2025
  15. Cell state transitions drive the evolution of disease progression in B-lymphoblastic leukemiaCancer Research Communications · 2025
  16. Identification of a two-gene biomarker correlated with sensitivity to combined PARP7 inhibition and AHR activation in cancer cellsCancer Research Communications · 2025
  17. Dipeptidyl peptidase 4 restoration facilitates anti-tumor immunity in KRAS-LKB1-mutant lung cancerCancer Research Communications · 2025
  18. Elevated tumor-associated androgen receptor activity correlates with poor immune infiltration and immunotherapy response across cancer typesCancer Research Communications · 2025
  19. Phase 1b Study of Dazostinag Plus Pembrolizumab After Hypofractionated Radiotherapy in Patients With Select Advanced Solid TumorsCancer Research Communications · 2025
  20. Cell state transitions drive the evolution of disease progression in B-lymphoblastic leukemiaCancer Research Communications · 2025
  21. Identification of a two-gene biomarker correlated with sensitivity to combined PARP7 inhibition and AHR activation in cancer cellsCancer Research Communications · 2025
  22. Dipeptidyl peptidase 4 restoration facilitates anti-tumor immunity in KRAS-LKB1-mutant lung cancerCancer Research Communications · 2025
  23. MicroCT enables simultaneous longitudinal tracking of murine pancreatic cancer progression and cachexiaCancer Research Communications · 2025
  24. Periostin promotes sarcoma growth by promoting tumor-associated macrophage migration and differentiationCancer Research Communications · 2025
  25. Periostin Promotes Sarcoma Growth by Promoting Tumor-Associated Macrophage Migration and DifferentiationCancer Research Communications · 2025
  26. Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Non-Squamous NSCLC with Pure Solid Tumor AppearanceCancer Research Communications · 2025
  27. Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor AppearanceCancer Research Communications · 2025
  28. Cancer Incidence and Mortality Estimates in Latin America and the Caribbean: A Systematic Analysis of the GLOBOCAN 2022Cancer Research Communications · 2025
  29. Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor PatientsCancer Research Communications · 2025
  30. Risk Factors Beyond Chemotherapy Exposure for Secondary Myeloid Neoplasms After Hematologic Cancers: A SEER-Based StudyCancer Research Communications · 2025
  31. Risk Factors beyond Chemotherapy Exposure for Secondary Myeloid Neoplasms after Hematologic Cancers: A SEER-Based StudyCancer Research Communications · 2025
  32. Association of neuronal autoantibodies with overall survival in gastric cancer patientsCancer Research Communications · 2025
  33. BrUOG360: A phase Ib/II study of copanlisib in combinationwith rucaparib in patients with metastatic castration-resistantprostate cancer (mCRPC)Cancer Research Communications · 2025
  34. Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric CancerCancer Research Communications · 2025
  35. BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Cancer Research Communications · 2025
  36. Blood-based Genomic Alteration Signature for Predicting Progression-free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World StudyCancer Research Communications · 2025
  37. Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World StudyCancer Research Communications · 2025
  38. Stand-alone transcriptional immune response prediction in primary triple-negative breast cancerCancer Research Communications · 2025
  39. Deep Learning Predicts EGFR Mutation Status from Histology Images in Non–Small Cell Lung CancerCancer Research Communications · 2025
  40. Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal CancerCancer Research Communications · 2025
  41. Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsCancer Research Communications · 2025
  42. Schlafen 12 Modulation and Targeting in Acute Myeloid LeukemiaCancer Research Communications · 2025
  43. Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal CancerCancer Research Communications · 2025
  44. A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic MalignanciesCancer Research Communications · 2025
  45. Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma XenograftsCancer Research Communications · 2025
  46. Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck CancerCancer Research Communications · 2025
  47. Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast CancerCancer Research Communications · 2025
  48. Impact of Tumor Burden on Immune Checkpoint and Conventional Therapy Responses and OutcomesCancer Research Communications · 2025
  49. The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)Cancer Research Communications · 2025
  50. Molecular characterization of oncogenic gene fusions in a large real-world cohort of solid tumorsCancer Research Communications · 2025